Results 191 to 200 of about 15,213,717 (386)

The Relationship between Emotional Perception and High-Density Built Environment Based on Social Media Data: Evidence from Spatial Analyses in Wuhan

open access: yesLand
The utilization of Social Media Data (SMD) from location-based services offers a wealth of information to analyze changes in human emotional perception influenced by high-density built environments.
Wei Liu   +3 more
doaj   +1 more source

Biodegradable Poly(butylene adipate‐co‐terephthalate)/Poly(lactic) Acid Mulch Film with Soy Waste Filler for Improved Biodegradation and Plant Growth

open access: yesAdvanced Energy and Sustainability Research, EarlyView.
The study finds that mulch films made with poly(butylene adipate‐co‐terephthalate)/poly(lactic acid) and 10% soy waste degrade faster than those without soy. Plants grown with the soy‐containing films are 49% taller, suggesting that the soy acts as a biostimulant.
Kerry Candlen   +8 more
wiley   +1 more source

Exploring Potentially Inappropriate Medication Use on Elderly Patients in a General Medicine Ward Using 2023 AGS Beers Criteria

open access: yesAGING MEDICINE, Volume 8, Issue 3, Page 238-248, June 2025.
This study found that 54% of elderly inpatients were prescribed at least one potentially inappropriate medication (PIM) based on the 2023 AGS Beers Criteria. Among identified PIMs, 32.2% were medications to avoid, and 52.8% required cautious use. Polypharmacy and chronic kidney disease (CKD) were key predictors of PIM use.
Subash Karki   +2 more
wiley   +1 more source

A Phase 3 Multicenter, Double‐Blind Study Comparing Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Alkem's Biosimilar Teriparatide Versus Reference Teriparatide in Postmenopausal Osteoporosis

open access: yesAGING MEDICINE, Volume 8, Issue 3, Page 267-274, June 2025.
This phase III study demonstrated that Alkem's biosimilar teriparatide is noninferior to reference teriparatide in improving bone mineral density at the lumbar spine and femoral neck in postmenopausal osteoporosis patients, with comparable safety, pharmacodynamics, and immunogenicity profiles over 48 weeks of treatment.
Nitin Kapoor   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy